Three-times rejected eye implant finally gets FDA nod for diabetic macular edema
This article was originally published in Clinica
Illuvien, an intravitreal implant that releases drugs in the back of the eye to treat diabetic macular edema (DME), has finally got the thumbs up from the US FDA, after having been rejected three times already by the agency. Shares of the product’s developers, Alimera and pSivida jumped during after-hours trading on 26 September when they revealed the news and they continued to rally before the markets opened on 29 September. Alimera’s share price rose about 22% in premarket trading on 29 September, while pSivida's stock climbed about 13%.